- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Abstract 434
FIBROSIS PROGRESSION IN INACTIVE HEPATITIS B VIRUS CARRIERS: A LONGITUDINAL STUDY WITH PAIRED LIVER STIFFNESS MEASUREMENTS
V.W.-S. Wong*, G.L.-H. Wong, Z. Yu, S.H.-T. Chu, H.-Y. Chan, C.-H. Tse, H.L.-Y. Chan
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. *[email protected]
Background and aims: The European Association for the Study of the Liver (EASL) defines inactive hepatitis B virus (HBV) carriers based on HBV DNA and alanine aminotransferase (ALT) levels. This study aimed to evaluate the risk of disease progression in such patients.
Methods: 417 patients with negative hepatitis B e antigen (HBeAg), HBV DNA < 20,000 IU/ml and normal ALT at baseline underwent liver stiffness measurement (LSM) by Fibroscan in 2006-2008 and again in 2010-2012. Fibrosis progression was defined as increase in LSM by 30% or more and an absolute LSM suggestive of advanced fibrosis at the second assessment.
Results: At baseline, the mean age was 49±11 years, 53% were males, ALT was 29±11 IU/l, HBV DNA was 2.7±0.9 log IU/ml, hepatitis B surface antigen (HBsAg) was 2.5 ±1.4 log IU/ml, and LSM was 6.4±3.2 kPa. 56 (13.4%) patients had advanced fibrosis at baseline. At an interval of 44±7 months, 10 of 361(2.8%) patients without advanced fibrosis at baseline developed fibrosis progression and 49 (13.6%) required antiviral therapy. Among 244 patients with baseline HBV DNA < 2,000 IU/ml, 11.9% had HBV DNA ≥20,000 IU/ml during follow-up, 8.2% required antiviral therapy and 2.9% had fibrosis progression. Corresponding figures in 117 patients with baseline HBV DNA 2,000-20,000 IU/ml were 16.4%, 24.8% and 2.6%, respectively (P< 0.001, < 0.001 and =0.76, respectively). The addition of HBsAg level to HBV DNA did not improve the prediction of outcomes.
Conclusions: Among patients with negative HBeAg and normal ALT, those with HBV DNA 2,000-20,000 IU/ml had similarly low risk of fibrosis progression but were more likely to develop indications for treatment than those with HBV DNA < 2,000 IU/ml.
Acknowledgements: This study was supported by the Research Fund for the Control of Infectious Diseases of the Hong Kong SAR Government (Ref 11100372).
Assigned speakers:
Dr. Vincent Wong, The Chinese University of Hong Kong , Hong Kong , China
Assigned in sessions:
25.04.2013, 09:00-18:00, Poster Session, P01-07b, Category 07b: Viral Hepatitis B & D: Clinical (except therapy), Poster Area
|
|